Improving safety and accuracy of brain biopsies for lymphoma patients
Official title: Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma (PCNSL): Integration of Advanced MRI Patterns and Fluorescein Sodium Fluorescence
Run by IRCCS San Raffaele · NCT06263361 · Data updated 2026-11-12
This study is testing if looking at MRI images can help doctors safely and accurately diagnose brain lymphoma in patients who might not be able to have regular biopsies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milan, Milan) |
| Status | Recruiting |
| Started | October 1, 2021 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | June 11, 2025 |
| Trial ID | NCT06263361 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult patients who are undergoing stereotactic biopsy for newly diagnosed primary central nervous system lymphomas.
✕Probably not a fit
Patients with severe hepatic, renal, or cardiac dysfunction, recent myocardial infarction or stroke, or those who are pregnant will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the MRI imaging characteristics of the peritumoral area in patients with primary central nervous system lymphoma (PCNSL) to correlate these findings with pathological results. By understanding different MRI patterns, the research aims to enhance the diagnostic potential for patients with deep-seated lesions who may not be eligible for traditional stereotactic biopsies. This observational study focuses on adult patients undergoing biopsy for newly diagnosed PCNSL, aiming to improve treatment outcomes through better diagnostic accuracy.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and improved treatment options for patients with primary central nervous system lymphoma.
How similar studies have gone: While this approach is focused on improving diagnostic accuracy for a specific condition, similar studies have shown promise in enhancing biopsy techniques and imaging correlations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients, undergoing stereotactic biopsy for newly diagnosed PSNCLs Exclusion Criteria: * Severe hepatic dysfunction * Severe renal dysfunction * Severe heart failure * myocardial infarction and stroke within 90 days * Hyperreactivity against contrast agents * Pregnancy
Where it's running
-
IRCCS San Raffaele Scientific Institute
Milan, Milan, Italy Recruiting
Study contacts
- Study coordinator: Laura Sincinelli
- Email: sincinelli.laura@hsr.it
- Phone: +390226435568
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.